Söndag 27 April | 04:29:04 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-01-27 07:30 Bokslutskommuniké 2025
2025-10-23 07:30 Kvartalsrapport 2025-Q3
2025-07-11 07:30 Kvartalsrapport 2025-Q2
2025-04-28 N/A X-dag ordinarie utdelning XVIVO 0.00 SEK
2025-04-25 - Årsstämma
2025-04-24 - Kvartalsrapport 2025-Q1
2025-01-28 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2024-04-25 - Årsstämma
2024-04-24 - Kvartalsrapport 2024-Q1
2024-01-25 - Bokslutskommuniké 2023
2023-10-24 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-04-26 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2023-04-25 - Årsstämma
2023-04-24 - Kvartalsrapport 2023-Q1
2023-01-26 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-13 - Kvartalsrapport 2022-Q2
2022-04-27 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2022-04-26 - Årsstämma
2022-04-25 - Kvartalsrapport 2022-Q1
2022-01-27 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-13 - Kvartalsrapport 2021-Q2
2021-04-23 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2021-04-22 - Årsstämma
2021-04-21 - Kvartalsrapport 2021-Q1
2021-01-28 - Bokslutskommuniké 2020
2020-10-23 - Kvartalsrapport 2020-Q3
2020-10-14 - Extra Bolagsstämma 2020
2020-07-10 - Kvartalsrapport 2020-Q2
2020-04-09 - Kvartalsrapport 2020-Q1
2020-04-01 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2020-03-31 - Årsstämma
2020-01-30 - Bokslutskommuniké 2019
2019-10-24 - Kvartalsrapport 2019-Q3
2019-07-12 - Kvartalsrapport 2019-Q2
2019-04-26 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2019-04-25 - Årsstämma
2019-04-24 - Kvartalsrapport 2019-Q1
2019-02-08 - Bokslutskommuniké 2018
2018-10-26 - Kvartalsrapport 2018-Q3
2018-07-13 - Kvartalsrapport 2018-Q2
2018-04-30 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2018-04-27 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-09 - Bokslutskommuniké 2017
2017-10-27 - Kvartalsrapport 2017-Q3
2017-07-14 - Kvartalsrapport 2017-Q2
2017-04-27 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2017-04-26 - Årsstämma
2017-04-25 - Kvartalsrapport 2017-Q1
2017-04-10 - Extra Bolagsstämma 2017
2017-02-08 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-07-15 - Kvartalsrapport 2016-Q2
2016-05-04 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2016-05-03 - Årsstämma
2016-04-26 - Kvartalsrapport 2016-Q1
2016-02-04 - Bokslutskommuniké 2015
2015-10-23 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-24 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2015-04-23 - Årsstämma
2015-04-22 - Kvartalsrapport 2015-Q1
2015-02-05 - Bokslutskommuniké 2014
2014-10-24 - Analytiker möte 2014
2014-10-24 - Kvartalsrapport 2014-Q3
2014-08-13 - Kvartalsrapport 2014-Q2
2014-04-30 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2014-04-29 - Årsstämma
2014-04-23 - Kvartalsrapport 2014-Q1
2014-02-07 - Bokslutskommuniké 2013
2013-11-07 - Analytiker möte 2013
2013-11-07 - Kvartalsrapport 2013-Q3
2013-07-11 - Kvartalsrapport 2013-Q2
2013-05-08 - X-dag ordinarie utdelning XVIVO 0.00 SEK
2013-05-07 - Årsstämma
2013-04-19 - Kvartalsrapport 2013-Q1
2013-02-19 - Bokslutskommuniké 2012
2012-11-01 - Kvartalsrapport 2012-Q3

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Xvivo Perfusion är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av system för organtransplantation och perfusion. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Bolagets produkter riktar sig till sjukvårdsinstitutioner och kirurger. Xvivo Perfusion är verksamt globalt, grundades 1998 och har sitt huvudkontor i Göteborg.
2022-05-19 15:00:00

The CHU Toulouse hospital in France has introduced both a liver and a lung machine perfusion program, now having the ability to significantly increase their transplant numbers. In a normal year they perform about 45 liver transplants and about 20 lung transplants and by that already fulfill the local requirement policy for organ transplantation. The machine perfusion programs also allow for utilization of organs donated after circulatory death (DCD).

France is the second largest transplant market in Europe. In 2020 1,112 liver transplants and 291 lung transplants were performed. The waiting list for a new liver or a new lung far exceeds the number of available organs. Machine perfusion is an innovative and proven technology to preserve and evaluate organs outside of the body which makes more donated organs accepted for transplantation.

A recent article in the American Journal of Transplantation showed that combining two commonly used protocols for liver machine perfusion using XVIVO’s Liver Assist enables safe transplantation of initially declined livers with excellent results, providing an effective tool to increase the number of suitable donor organs for transplantation[1].

“Starting two machine perfusion programs show our dedication to give more patients a life-changing transplant. Having the possibility to evaluate organs outside of the body is extremely valuable, which is not possible with traditional cold static preservation on ice. Running the ex vivo lung perfusion program I personally believe we will shorten the time on the waiting list now when more organs can be used. Initially we expect an increase in lung transplants by 20 percent”, says Pierre Rabinel, MD Thoracic Surgery at the CHU Toulouse hospital.

“It makes me very happy that CHU Toulouse starts two programs this year using XVIVO’s technologies. I would say that it is a global trend that hospitals set up machine perfusion programs for all major organs. Full perfusion centers for livers, lungs, kidneys and hearts are being established all around the world, and they are needed. For example, in 2020 only 16 percent of all donated available lungs where used. Machine perfusion will change that number”, says Dag Anderson, CEO of XVIVO.
 
 
May 19, 2022
Gothenburg
Dag Andersson, CEO
XVIVO Perfusion AB (publ)


[1] van Leeuwen, O.B., et al., Sequential Hypothermic and Normothermic Machine Perfusion Enables Safe Transplantation of High-risk Donor Livers. Am J Transplant, 2022